Novo Nordisk A S (ADR) (NVO) Analysts See $0.56 EPS; Eagle Bancorp Montana (EBMT)’s Sentiment Is 2.6

August 8, 2017 - By Adrian Mccoy

Analysts expect Novo Nordisk A S (ADR) (NYSE:NVO) to report $0.56 EPS on August, 9 before the open.They anticipate $0.04 EPS change or 6.67% from last quarter’s $0.6 EPS. NVO’s profit would be $1.10B giving it 18.60 P/E if the $0.56 EPS is correct. After having $0.58 EPS previously, Novo Nordisk A S (ADR)’s analysts see -3.45% EPS growth. The stock decreased 0.95% or $0.4 on August 7, reaching $41.66. About shares traded. Novo Nordisk A S (ADR) (NYSE:NVO) has declined 23.93% since August 8, 2016 and is downtrending. It has underperformed by 40.63% the S&P500.

Eagle Bancorp Montana, Inc. is the bank holding firm for Opportunity Bank of Montana . The company has market cap of $69.75 million. The Bank is a Montana-chartered commercial bank. It has a 14.04 P/E ratio. The Bank has equity investments in Certified Development Entities, which have received allocations of New Markets Tax Credits (NMTC).

Glacier Peak Capital Llc holds 4.46% of its portfolio in Eagle Bancorp Montana Inc for 367,768 shares. Oppenheimer & Close Llc owns 112,250 shares or 2.13% of their US portfolio. Moreover, Minerva Advisors Llc has 0.3% invested in the company for 25,598 shares. The Florida-based Naples Global Advisors Llc has invested 0.16% in the stock. Deprince Race & Zollo Inc, a Florida-based fund reported 199,932 shares.

The stock increased 0.27% or $0.05 on August 7, reaching $18.3. About shares traded. Eagle Bancorp Montana Inc (EBMT) has risen 42.05% since August 8, 2016 and is uptrending. It has outperformed by 25.35% the S&P500.

Novo Nordisk A/S is a global healthcare firm engaged in diabetes care. The company has market cap of $81.89 billion. The Firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. It has a 17.19 P/E ratio. The Firm operates through two business divisions: diabetes and obesity care, and biopharmaceuticals.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts

Twitter Auto Publish Powered By : XYZScripts.com